Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI - Trial NCT06277674
Access comprehensive clinical trial information for NCT06277674 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangzhou University of Traditional Chinese Medicine and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guangzhou University of Traditional Chinese Medicine
Timeline & Enrollment
Phase 2
Nov 02, 2023
Jun 01, 2025
Primary Outcome
ORR(Objective response rate)
Summary
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and
 CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of
 elderly patients with T790M-negative advanced non-squamous non-small cell lung cancer
 following resistance to EGFR-TKI.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06277674
Non-Device Trial